Ascletis Pharma Inc. disclosed via a Next Day Disclosure Return (9 June 2026) that it repurchased an additional 200,000 ordinary shares on 9 June 2026. The on-market purchases were executed at prices between HKD 9.80 and HKD 10.28 per share, for a total consideration of HKD 2.01 million, implying an average purchase price of HKD 10.07 per share.

As at the close of 9 June 2026, the company’s share capital comprised 1.06 billion issued shares (excluding treasury shares), unchanged from the previous day. Treasury shares stood at 7.08 million, reflecting ongoing but not yet cancelled buybacks.

Since the current repurchase mandate was approved on 22 May 2025, Ascletis Pharma has bought back 7.49 million shares, representing 0.78 % of the company’s issued share capital at the date of the mandate. The mandate permits repurchases of up to 96.28 million shares, leaving more than 88 million shares, or about 92 % of the authorised limit, still available.

Pending cancellation, a total of 6.99 million shares repurchased between April 2025 and 9 June 2026 remain in treasury at an aggregate cost reflecting individual transaction prices ranging from HKD 4.85 to HKD 14.58 per share.

Under Hong Kong Stock Exchange rules, Ascletis Pharma is subject to a 30-day moratorium on issuing new shares or selling treasury shares, effective until 9 July 2026.